Charmacy Pharmaceutical Co., Ltd.

SEHK:2289 株式レポート

時価総額:HK$928.8m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Charmacy Pharmaceutical バランスシートの健全性

財務の健全性 基準チェック /26

Charmacy Pharmaceuticalの総株主資本はCN¥597.8M 、総負債はCN¥1.3Bで、負債比率は223.7%となります。総資産と総負債はそれぞれCN¥3.2BとCN¥2.6Bです。 Charmacy Pharmaceuticalの EBIT はCN¥108.3Mで、利息カバレッジ比率3です。現金および短期投資はCN¥644.8Mです。

主要情報

223.7%

負債資本比率

CN¥1.34b

負債

インタレスト・カバレッジ・レシオ3x
現金CN¥644.76m
エクイティCN¥597.81m
負債合計CN¥2.65b
総資産CN¥3.25b

財務の健全性に関する最新情報

Recent updates

There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

May 13
There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased

There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

Apr 24
There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump

Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jan 19
Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

Oct 25
These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well

If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

Sep 17
If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity

Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

May 02
Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?

What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Mar 15
What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

Feb 17
Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?

We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Jan 27
We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide

Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

Jan 09
Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture

What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Dec 22
What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us

Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

Nov 29
Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years

財務状況分析

短期負債: 2289の 短期資産 ( CN¥2.8B ) が 短期負債 ( CN¥2.6B ) を超えています。

長期負債: 2289の短期資産 ( CN¥2.8B ) が 長期負債 ( CN¥31.0M ) を上回っています。


デット・ツー・エクイティの歴史と分析

負債レベル: 2289の 純負債対資本比率 ( 115.9% ) は 高い と見なされます。

負債の削減: 2289の負債対資本比率は、過去 5 年間で218.4%から223.7%に増加しました。

債務返済能力: 2289の 営業キャッシュフロー はマイナスであるため、負債は十分にカバーされていません。

インタレストカバレッジ: 2289の負債に対する 利息支払いEBIT ( 3 x coverage) によって 十分にカバーされていません


貸借対照表


健全な企業の発掘